Westminster Health Forum

The future of biosimilars in the UK: regulation, access and medicines optimisation

Thursday, 8th June 2017

Central London

THIS EVENT IS CPD CERTIFIED



This seminar will provide the opportunity to discuss the future of biosimilar medicines in the UK.

Delegates will assess the next steps for regulation and pharmacovigilance, the impact of increased competition between originator and biosimilar manufacturers and the challenges for embedding use in service delivery following the publication of NHS England’s ‘What is a biosimilar medicine?’ guide.

Sessions will also focus on the implications of the UK vote to leave the European Union on access to biosimilars, key issues for clinicians around switching from originator to biosimilar - and the next steps for patient engagement, education and involvement.


Guest of Honour

Dr Christian Schneider

Director, National Institute for Biological Standards and Control, MHRA

Guest of Honour

Dr Christian Schneider

Director, National Institute for Biological Standards and Control, MHRA

Keynote Speaker

Jonathan Underhill

Medicines Clinical Adviser, Medicines and Prescribing Programme, NICE

Speakers

Natasha Pearman

Managing Associate, Mishcon de Reya

Tim de Gavre

Chair, British Biosimilars Association and Business Unit Head, Sandoz

Dr Virginia Acha

Executive Director, Research, Medical & Innovation, ABPI